Optherion
Optherion, Inc. develops therapeutics for early-stage age-related macular degeneration and other diseases in the US.
Founded
2005Optherion, Inc. develops therapeutics for early-stage age-related macular degeneration and other diseases in the US.
Optherion, Inc. was founded with the mission to develop diagnostic and disease-modifying therapeutics aimed at managing and treating early-stage age-related macular degeneration (AMD) and other diseases related to the alternative complement cascade. The company's vision is to provide innovative solutions that address significant unmet medical needs in the field of ophthalmology and beyond. Optherion offers a range of products and services including molecular diagnostics, point-of-care testing (POCT), and nucleic acid testing (NAT), focusing primarily on the U.S. market.
Notable affiliated individuals and investors in Optherion include experts in ophthalmology and biotechnology, though specific names are not publicly detailed. The company has achieved significant milestones in developing cutting-edge diagnostics and therapeutic solutions, contributing to advancements in the treatment of AMD and related conditions. Optherion's impact is marked by its commitment to improving patient outcomes through innovative medical technologies and its role in advancing the field of molecular diagnostics.
Companies similar to Optherion include EyeCyte, Ocudyne, Macuclear and i-Lumen Scientific.
Optherion was founded in 2005.
Optherion's headquarters is located in New Haven, CT, US.
Optherion's most recent funding round was for $5M (USD) in September 2009.
As of Sep 16, 2009, Optherion has disclosed funding of $42M (USD). Undisclosed round amounts are excluded.
Optherion has 11 employees as of Feb 5, 2024.
i-lumen.com
